07:08 AM EDT, 07/21/2025 (MT Newswires) -- AstraZeneca ( AZN ) said Monday that a final overall survival analysis of its phase 3 study for patients with 1st line locally advanced or metastatic epidermal growth factor receptor-mutated, or EGFRm, non-small cell lung cancer showed improvement in key secondary endpoints.

The FLAURA2 phase 3 study evaluated Tagrisso in combination with pemetrexed and platinum-based chemotherapy in patients with EGFRm lung cancer.

"Tagrisso plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer," the company said.

The latest analysis is in line with the interim overall survival report and builds on the previously presented primary endpoint data, which demonstrated the longest-reported median progression-free survival in this setting, AstraZeneca ( AZN ) said.